0001209191-21-058530.txt : 20211001
0001209191-21-058530.hdr.sgml : 20211001
20211001171642
ACCESSION NUMBER: 0001209191-21-058530
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210901
FILED AS OF DATE: 20211001
DATE AS OF CHANGE: 20211001
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galante Joseph C
CENTRAL INDEX KEY: 0001632384
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 211299957
MAIL ADDRESS:
STREET 1: 111 TENTH AVENUE
STREET 2: SUITE 200
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-01
0
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001632384
Galante Joseph C
2525 WEST END AVENUE
SUITE 950
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2021-09-01
4
P
0
142
2.88
A
37955
D
Common Stock
2021-09-02
4
P
0
142
2.88
A
38097
D
Common Stock
2021-09-03
4
P
0
142
2.85
A
38239
D
Common Stock
2021-09-07
4
P
0
142
2.79
A
38381
D
Common Stock
2021-09-08
4
P
0
142
2.89
A
38523
D
Common Stock
2021-09-09
4
P
0
142
2.77
A
38665
D
Common Stock
2021-09-10
4
P
0
142
2.78
A
38807
D
Common Stock
2021-09-13
4
P
0
142
2.96
A
38949
D
Common Stock
2021-09-14
4
P
0
142
3.02
A
39091
D
Common Stock
2021-09-15
4
P
0
142
2.86
A
39233
D
Common Stock
2021-09-16
4
P
0
142
2.91
A
39375
D
Common Stock
2021-09-17
4
P
0
142
2.85
A
39517
D
Common Stock
2021-09-20
4
P
0
142
2.82
A
39659
D
Common Stock
2021-09-21
4
P
0
142
2.81
A
39801
D
Common Stock
2021-09-22
4
P
0
142
2.76
A
39943
D
Common Stock
2021-09-23
4
P
0
142
2.75
A
40085
D
Common Stock
2021-09-24
4
P
0
142
2.74
A
40227
D
Common Stock
2021-09-27
4
P
0
142
2.79
A
40369
D
Common Stock
2021-09-28
4
P
0
142
2.76
A
40511
D
Common Stock
2021-09-29
4
P
0
142
2.82
A
40653
D
Common Stock
2021-09-30
4
P
0
142
2.72
A
40795
D
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.
Joseph C. Galante by /s/ John Hamm as
attorney-in-fact
2021-10-01